hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06266403, orgStudyIdInfo id: STUDY00024154, briefTitle: Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2029-03, completionDateStruct date: 2029-03, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Penn State University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.The question is, What are the effects of communicative interaction on verbal communication in people with ALS?Participants will read words and sentences while they are in a solo setting and interactive setting., conditionsModule conditions: Amyotrophic Lateral Sclerosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: PALS and age-matched adults will participate in one solo speech production task (clear speech) and three interactive tasks (structured communicative interaction, unstructured communicative interaction, and clear speech structured communicative interaction) in which they work with an unfamiliar, naive interlocutor. This study is designed to examine the differences in speech produced in the four tasks. Comparisons of speech produced by PALS and age-matched adults will clarify whether differences in speech observed across the four tasks are a function of the speech difficulties experiences by PALS.Plans for Assignment - This is a single group study in which all participants will engage in the same tasks., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Structured Communicative Interaction, interventions name: Clear Speech, interventions name: Unstructured communicative interaction, interventions name: Clear Speech Structured Communicative Interaction, outcomesModule primaryOutcomes measure: Formant frequencies of speech sounds, primaryOutcomes measure: Intelligibility of recorded speech, primaryOutcomes measure: Syntactic properties, primaryOutcomes measure: Pragmatic Properties, primaryOutcomes measure: Duration of speech sounds, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06266390, orgStudyIdInfo id: 855007, briefTitle: Engaging sgACC With TMS for Depression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2026-01-30, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: The purpose of this study is to investigate the responses of the brain region known as the subgenual anterior cingulate cortex (sgACC) during transcranial magnetic stimulation (TMS) in individuals with depression. Specifically, investigators aim to determine whether the sgACC is engaged when TMS is delivered to specific targets and if the engagement of sgACC changes throughout a full TMS treatment intervention. To achieve this goal, the investigators will employ a combination of TMS and Magnetic Resonance Imaging (MRI) procedures.Study participation will include completing various questionnaires, clinical assessments, receiving a full transcranial magnetic stimulation (TMS) treatment intervention (every weekday for 4-6 weeks), and undergoing MRI scans, both with and without concurrent TMS., conditionsModule conditions: Depression, conditions: Major Depressive Disorder, conditions: Persistent Depressive Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will receive rTMS to one of two targets. Participants will be randomly assigned to receive the TMS treatment intervention in one of two target conditions: half to their positive sgACC correlation target, while the remaining half to their negative sgACC correlation target., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Participants will not be informed on which target they have been assigned to., whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial Magnetic Stimulation (TMS), outcomesModule primaryOutcomes measure: sgACC Blood Oxygen Level Dependent (BOLD) signal change following single-pulse fMRI-guided TMS (TMS On vs TMS Off), secondaryOutcomes measure: Change in sgACC evoked response Pre/Post TMS treatment with positive and negative sgACC correlated targets, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Pennsylvania, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, contacts name: Almaris Figueroa-González, role: CONTACT, email: almaris.figuera-gonzalez@pennmedicine.upenn.edu, contacts name: Ethan Hammett, role: CONTACT, email: ethan.hammett@pennmedicine.upen.edu, contacts name: Desmond J Oathes, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06266377, orgStudyIdInfo id: 11122023, briefTitle: AUT-MENU: Improving Meal Experience of Subjects With Autism Spectrum Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University of Pavia, class: OTHER, collaborators name: Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria (CREA), descriptionModule briefSummary: The main goal of this multi-center interventional study is to improve the meal experience of children and adolescents with autism spectrum disorder trough the development of menus for collective catering targeted to their nutritional and sensory needs and the drafting of nutritional indications that can be a reference for collective catering nationwide. After an initial assessment of participants' consumption of meals in the collective service, menus adapted to their nutritional and sensory needs will be administered, and consumption between the initial and adapted menus will be compared. A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Non-randomized multi-center intervention with a single arm. Study participants will receive new adapted canteen menus according to the nutritional and sensory needs of the target population., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder, interventions name: Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder, outcomesModule primaryOutcomes measure: Food acceptance of canteen menus by individuals enrolled in the study, secondaryOutcomes measure: Reduction in food selectivity as a result of the targeted nutrition education course, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Milano Ristorazione S.p.A., city: Milano, zip: 20139, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Istituto I.P.S.E.O.A. "Tor Carbone - A. Narducci"., city: Roma, zip: 00178, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, locations facility: Istituto Tecnico Agrario Statale "Giuseppe Garibaldi", city: Roma, zip: 00178, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06266364, orgStudyIdInfo id: IRB-24-22, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06266351, orgStudyIdInfo id: LASIKIOP, briefTitle: EVALUATION OF CATS TONOMETER PRISM IN LASIK SUBJECTS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Intuor Technologies, Inc., class: INDUSTRY, descriptionModule briefSummary: The CATS Tonometer prism clinical study is intended to determine repeatability of intraocular pressure measurement in human corneas which have undergone a LASIK procedure when compared to a standard Goldmann prism, validating the human LASIK eye findings comparing CATS Tonometer and Goldmann prisms to intracameral pressure in cadaver eyes., conditionsModule conditions: Glaucoma, conditions: Ocular Hypertension, conditions: Normal Tension Glaucoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: This is observational IOP measurement, outcomesModule primaryOutcomes measure: IOP measurement difference between CATS and GAT in LASIK patients, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Arizona Eye Consultants, city: Tucson, state: Arizona, zip: 85710, country: United States, geoPoint lat: 32.22174, lon: -110.92648, locations facility: Eye Specialty Group, city: Memphis, state: Tennessee, zip: 38120, country: United States, contacts name: Sean Dodson, role: CONTACT, phone: 520-327-3487, email: sjmccafferty66@hotmail.com, geoPoint lat: 35.14953, lon: -90.04898, hasResults: False
protocolSection identificationModule nctId: NCT06266338, orgStudyIdInfo id: STU-2023-1118, briefTitle: Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2026-10-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: University of Texas Southwestern Medical Center, class: OTHER, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab has any effect on slowing tumor growth in cervical cancer tumors., conditionsModule conditions: Cervix Cancer, conditions: Cervical Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab, interventions name: Lenvatinib, outcomesModule primaryOutcomes measure: Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1, secondaryOutcomes measure: Progression Free Survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors v1.1, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UT Southwestern Medical Center, status: RECRUITING, city: Dallas, state: Texas, zip: 75390, country: United States, contacts name: Annette Paulsen, role: CONTACT, phone: 214-648-7097, contacts role: CONTACT, email: annette.paulsen@utsouthwestern.edu, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06266325, orgStudyIdInfo id: 6138, briefTitle: Development and Validation of a Dementia Life Expectancy Tool, statusModule overallStatus: COMPLETED, startDateStruct date: 2010-04-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2022-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Toronto, class: OTHER, collaborators name: Sunnybrook Research Institute, collaborators name: Ottawa Hospital Research Institute, collaborators name: ICES, descriptionModule briefSummary: Individuals with dementia and their caregivers are faced with challenging decisions throughout the course of the disease. These decisions may be about medical care (e.g., continuation of routine cancer screening, pursuit of cardiopulmonary resuscitation, initiation of palliative care services), institutionalization (i.e., transition to a long-term care facility), or financial planning. These inherently difficult decisions are made more difficult by prognostic uncertainty. Indeed, life expectancy is challenging to predict in dementia. Consequently, prognosis is infrequently discussed by healthcare providers with individuals with dementia and their families, which compromises their ability to plan for the future. A lack of prognostic awareness makes it difficult for patients, their caregivers, and their healthcare providers to make medical decisions that strike the appropriate balance between prolonging life and promoting the quality of it. A clinical prediction tool has the promise to provide personalized and accurate estimations of life expectancy in individuals with dementia. Therefore, similar to the existing clinical prediction tools on our Project Big Life platform (www.projectbiglife.ca), we seek to create and to test a statistical model to predict survival, and to implement the model as a user-friendly, web-based calculator. The calculator will use self-reported sociodemographic, clinical, cognitive, functional, and nutritional information that is entered by patients, their caregivers, and/or their healthcare providers to output an estimated life expectancy. This estimate could inform the shared decision-making process, thereby empowering decisions that are compatible with a patient's clinical reality and concordant with their life goals., conditionsModule conditions: Dementia, conditions: Death, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 202217, type: ACTUAL, armsInterventionsModule interventions name: There is no intervention. Exposures are predictor variables of mortality., outcomesModule primaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06266299, orgStudyIdInfo id: 2269-001, briefTitle: A Study of KK2269 in Adult Participants With Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Kyowa Kirin, Inc., class: INDUSTRY, descriptionModule briefSummary: This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269.In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies.In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible., conditionsModule conditions: Advanced Solid Tumor, conditions: Metastatic Solid Tumor, conditions: Gastric Adenocarcinoma, conditions: Gastroesophageal Junction Adenocarcinoma, conditions: Esophageal Adenocarcinoma, conditions: Non Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 71, type: ESTIMATED, armsInterventionsModule interventions name: KK2269, interventions name: Docetaxel, outcomesModule primaryOutcomes measure: Number of Subjects Experiencing Dose-limiting Toxicity, primaryOutcomes measure: Number of Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center Hospital East, status: RECRUITING, city: Kashiwa City, state: Chiba, zip: 277-8577, country: Japan, geoPoint lat: 35.86224, lon: 139.97732, locations facility: National Cancer Center Hospital, status: RECRUITING, city: Chuo-ku, state: Tokyo, zip: 104-0045, country: Japan, geoPoint lat: 35.57779, lon: 139.71685, hasResults: False
protocolSection identificationModule nctId: NCT06266273, orgStudyIdInfo id: SBA 23/442, briefTitle: Investigating the Development, Validity, and Reliability of the Avoidance of Sports Activities Photo Scale, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, descriptionModule briefSummary: "Investigating the Development, Validity, and Reliability of the Avoidance of Sports Activities Photo Scale" is crucial in determining the specific functional status of the shoulder joint, especially for overhead athletes experiencing shoulder pain, to identify which sporting activities restrict them the most and to fill the gap in the literature. Additionally, visually indicating activities through photographs will provide visual feedback, making it easier to assess functional status. Our study aims to develop a specific functional survey for the shoulder joint in overhead athletes, examine the validity and reliability of this scale, and contribute to the literature., conditionsModule conditions: Questionnaire, conditions: Athletes, conditions: Shoulder Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 170, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Investigating the Development, Validity, and Reliability of The Sports Activity Avoidance Photo Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Elif Turgut, status: RECRUITING, city: Ankara, zip: 06300, country: Turkey, contacts name: Elif Turgut, Assoc. Prof., role: CONTACT, phone: +90 (544) 264 56 00, email: elif.turgut.pt@gmail.com, contacts name: Birgül DINGIRDAN, Master, role: SUB_INVESTIGATOR, contacts name: Büşra PAKÖZ, Master, role: SUB_INVESTIGATOR, contacts name: Kübra ÇAYLAN GÜRSES, Master, role: SUB_INVESTIGATOR, contacts name: Pınar KUYULU HAKSAL, Master, role: SUB_INVESTIGATOR, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06266260, orgStudyIdInfo id: 5486, briefTitle: Evaluation of the Performance of Direct Portal Pressure Measurement by Endoscopic Ultrasound in a Large Cohort of Patients With Advanced Chronic Liver Disease of Different Etiologies and Newly Diagnosed Clinically Significant Portal Hypertension (EVADIPP), acronym: EVADIPP, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-11, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: A minimally invasive procedure to directly assess portal pressure gradient under endoscopic ultrasound guidance (EUS-PPG) has become available and initial data have proved the technique to be safe. Aims of our proposal are: (i) to assess performance of EUS-PPG as compared to HVPG in evaluating hemodynamic response to non selective betablockers (NSBBs) in a large cohort of patients with CSPH;(ii) identification of markers of hemodynamic response(iii) identification of factors potentially affecting the accuracy of PPG measurement., conditionsModule conditions: Portal Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: EUS PPG measurement, outcomesModule primaryOutcomes measure: Measurement of the portal pressure gradient though endoscopic ultrasound (EUS) and hepatic venous pressure gradient (HVPG) to evaluate the hemodynamic response to non-selective beta blockers (NSBBs), primaryOutcomes measure: Measurement of the portal pressure gradient though endoscopic ultrasound (EUS) and hepatic venous pressure gradient (HVPG) to evaluate the hemodynamic response to non-selective beta blockers (NSBBs), secondaryOutcomes measure: Markers of hemodynamic response, secondaryOutcomes measure: Markers of hemodynamic response, secondaryOutcomes measure: Markers of hemodynamic response, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Policlinico Gemelli IRCCS, status: RECRUITING, city: Roma, zip: 00168, country: Italy, contacts name: Francesco Santopaolo, MD, role: CONTACT, phone: +393492754288, email: francesco.santopaolo@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False